These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Neoplasm Risk in Patients With Rheumatoid Arthritis Treated With Fostamatinib: A Systematic Review and Meta-analysis. Chen Y; Liu H; Tian Y; Luo Z; Yin G; Xie Q Front Pharmacol; 2022; 13():768980. PubMed ID: 35308252 [No Abstract] [Full Text] [Related]
43. Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials. Du Y; Cao G; Gu L; Chen Y; Liu J Front Pharmacol; 2023; 14():1237583. PubMed ID: 38273834 [No Abstract] [Full Text] [Related]
45. The Cardiovascular Risks of Fostamatinib in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Chen Y; Liu H; Huang Y; Lin S; Yin G; Xie Q Front Pharmacol; 2021; 12():632551. PubMed ID: 34349639 [No Abstract] [Full Text] [Related]
46. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Boccia R; Cooper N; Ghanima W; Boxer MA; Hill QA; Sholzberg M; Tarantino MD; Todd LK; Tong S; Bussel JB; Br J Haematol; 2020 Sep; 190(6):933-938. PubMed ID: 33439486 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Kang Y; Jiang X; Qin D; Wang L; Yang J; Wu A; Huang F; Ye Y; Wu J Front Pharmacol; 2019; 10():897. PubMed ID: 31474860 [No Abstract] [Full Text] [Related]
48. Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. De Cock D; Hyrich K Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):869-886. PubMed ID: 31427060 [TBL] [Abstract][Full Text] [Related]
49. Causes of Death in Rheumatoid Arthritis: How Do They Compare to the General Population? Widdifield J; Paterson JM; Huang A; Bernatsky S Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1748-1755. PubMed ID: 29512334 [TBL] [Abstract][Full Text] [Related]
50. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Mercer LK; Askling J; Raaschou P; Dixon WG; Dreyer L; Hetland ML; Strangfeld A; Zink A; Mariette X; Finckh A; Canhao H; Iannone F; Zavada J; Morel J; Gottenberg JE; Hyrich KL; Listing J Ann Rheum Dis; 2017 Feb; 76(2):386-391. PubMed ID: 27307502 [TBL] [Abstract][Full Text] [Related]
52. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials. Kunwar S; Devkota AR; Ghimire DK Rheumatol Int; 2016 Aug; 36(8):1077-87. PubMed ID: 27113955 [TBL] [Abstract][Full Text] [Related]
53. Comorbidities in rheumatoid arthritis. Dougados M Curr Opin Rheumatol; 2016 May; 28(3):282-8. PubMed ID: 27027814 [TBL] [Abstract][Full Text] [Related]
54. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Michaud K; Nyberg F; Pappas DA; Reed G; Tanaka E; Tran TN; Verstappen SM; Yamanaka H; Wesby-van Swaay E; Symmons D Ann Rheum Dis; 2016 Oct; 75(10):1789-96. PubMed ID: 26621482 [TBL] [Abstract][Full Text] [Related]